semaj83/ctmatch_classification huggingface dataset:
Patient description: A 27-year-old woman at 11 weeks gestation in her second pregnancy is found to have a hemoglobin (Hb) of 9.0 g/dL, white blood cell count 6.3 x 109/L, platelet count 119 x 109/L, mean corpuscular volume 109 fL. Further investigations reveal mild iron deficiency. She already receives iron supplementation. The obstetrician repeats the complete blood cell count 2 weeks later. The Hb is 8.9 g/dL, WBC count 7.1 x 109/L, and platelets 108 x 109/L. She describes difficulty swallowing. A reticulocyte count is performed and found elevated at 180 x 109/L. The obstetrician requests a hematology consult. The following additional results were found: Negative DAT, normal clotting screen, elevated LDH (2000 IU/L), normal urea and electrolytes, normal alanine aminotransferase (ALT), anisocytosis, poikilocytosis, no fragments, no agglutination, polychromasia and presence of hemosiderin in the urine.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Anemia, Iron-Deficiency Hemoglobin (Hb) < 120 g/L in men and Hb < 110 g/L in women; Mean Corpuscular Volume(MCV) < 80 fl, Mean Corpuscular Hemoglobin(MCH) < 27 pg, and Mean Corpuscular Hemoglobin Concentration(MCHC) < 0.32; the blood biochemical examination: serum ferritin < 12 g/L, serum iron < 8.95 mol/L, transferrin saturation <15%, and total iron binding capacity>64.44 mol/L; with a history of Menorrhagia, monophagia or eating disorders; Willing to sign a Informed consent form  Pregnant women; drug allergy; the patients with serious gastrorrhagia, other peptic ulcers, active bleeding, hepatic insufficiency, heart disease or renal insufficiency; those patients can't tolerate the medicine orally, or participate in other clinical study, or refuse to sign a Informed consent Form
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases Men and women, aged 60 or over. Isolated systolic hypertension. Normal diastolic pressure of less than 90 mm Hg
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Arrhythmia Atrial Fibrillation Cardiovascular Diseases Heart Diseases Elderly men and women with atrial fibrillation and other risk factors for stroke
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Carotid Atherosclerosis Cerebrovascular Accident Diabetes Mellitus Hypercholesterolemia Hypertension Male or female greater than 18 years of age Patient must have documented hypertension (diastolic BP greater than 90 mmHg or systolic BP greater than 140 mmHg) for greater than 1 year OR hypercholesterolemia (LDL greater than 160 or total Chol greater than 240 with a total cholesterol/HDL-Chol ratio more than 1.6 for greater that 1 year OR Diabetes (blood glucose greater than 150 mg/dl requiring oral antihyperglycemics or insulin dependent) for greater than 1 year OR any combination Subgroup for risk factors with cerebral ischemic events must meet #2 plus documented stroke by physical exam and CT and/or MRI consistent with ischemic infarction or TIA witnessed and recorded by medical personnel Patient will be excluded if enrollment time is within 30 days of a stroke, myocardial infarction, or surgery. Patient may be enrolled after 30 days of the above events No patients on immunosuppressive therapy No patients who are unable to follow up for 1 year from the time of enrollment No stroke patients with an identifiable cardiac source (including atrial fibrillation, mural thrombus, valvular disease with vegetation)
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cardiomyopathy, Hypertrophic Heart Hypertrophy Patients of either gender, aged 18-75 years, with HCM caused by sarcomeric gene mutations determined by existing protocols LV wall thickness of greater than or equal to 20 mm measured in any LV segment by MRI Severe symptoms refractory to medical treatment (New York Heart Association functional class III or IV) No LV outflow tract obstruction at rest greater than 30 mm Hg as determined by cardiac catheterization No coronary artery disease (greater than 50% arterial luminal narrowing of a major epicardial vessel) No chronic atrial fibrillation No bleeding disorder (PTT greater than 35 sec, pro time greater than 14 sec, platelet count less than 154 k/mm(3) No anemia (Hb less than 12.7 g/dl in males and less than 11.0 g/dl in females) No renal impairment (serum creatinine greater than 1.3 mg/dl) No hepatitis B or C; nor unexplained abnormal LFTs
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cardiovascular Diseases Coronary Disease Cerebrovascular Accident Heart Diseases Heart Failure, Congestive Myocardial Infarction Asthma Emphysema Lung Diseases, Obstructive Aortic Aneurysm, Abdominal Bronchitis Dementia Hypertension Chronic Obstructive Pulmonary Disease Heart Failure
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Cardiovascular Diseases Coronary Disease Heart Diseases Cerebrovascular Accident Diabetes Mellitus Hypertension Heart Failure, Congestive
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cardiovascular Diseases Heart Diseases Hypertension Carotid Artery Diseases Atherosclerosis
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cardiomyopathy, Hypertrophic HCM Patients HCM defined as maximal LV wall thickness by echocardiography greater than 13mm in the absence of other causes of LVH or greater than 15mm asymmetrical LV wall thickness if there is a history of mild hypertension (defined as systolic less than 160mmHg and diastolic less than 100mHg) controlled for greater than 6 months Non-obstructive HCM Age greater than or equal to 21 years Patients with LV obstruction treated by LV myotomy and myectomy or percutaneous septal alcohol ablation that meet are eligible for this study  HCM Patients LV outflow obstruction noted during Doppler echocardiography at rest or with Valsalva maneuver defined as instantaneous peak gradient greater than 30 mmHg Hemodynamically significant valvular disorders, history of significant coronary obstruction (greater than 50% in any single artery), angina symptoms, myocardial ischemia on an imaging stress test or evidence of prior myocardial infarction. Patients older than 40 years of age with effort induced anginal symptoms typical of coronary insufficiency and a coronary distribution of myocardial ischemia on an imaging stress test will be considered for the study if coronary angiography rules out significant obstructive coronary disease Chronic atrial fibrillation Cardiac pacemaker or other metallic implant unsafe for MRI Uncontrolled hypertension Dependence on a beta blocker that cannot be withdrawn Dependence on a calcium blocker that cannot be withdrawn Current use of digoxin History of digitalis intolerance
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Ischemic Stroke Acute ischemic stroke, any territory, with an appropriate neuroradiologic study (head CT scan or brain MRI scan) providing results consistent with non hemorrhagic stroke Onset of symptoms of qualifying stroke within 48 hours prior to randomization. In patients receiving thrombolytic therapy for the acute stroke, such as tissue-type plasminogen activator (tPA), administration of study drug may not start until at least 24 hours after completion of thrombolytic therapy Significant motor impairment of the leg, as indicated by a NIHSS score ≥2 on item 6 Inability to walk without assistance  Females who are pregnant, breast-feeding, or of childbearing potential and not using medically acceptable and effective contraception Clinical evidence of VTE at screening Any evidence of active bleeding on the basis of clinical judgment Prior history of intracranial hemorrhage (including that at screening) Spinal or epidural analgesia or lumbar puncture within the preceding 24 hours Thrombolytic therapy (e.g., tPA) or intra-arterial thrombolytic therapy within the preceding 24 hours.Thrombolytic therapy is permitted for treatment of the acute stroke but must have been completed 24 hours prior to randomization Comatose at screening (NIHSS score ≥2 on item 1a) Known or suspected cerebral aneurysm or arteriovenous malformation Confirmed malignancy that may pose an increased risk for bleeding or otherwise compromise follow-up or outcome assessment (e.g., lung cancer) Impaired hemostasis, i.e., known or suspected coagulopathy (acquired or inherited); baseline platelet count <100,000/mm3; aPTT 1.5 X the laboratory upper limit of normal; or international normalized ratio(INR) >1.5
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypertension, Pulmonary Pilot: The pilot study will enroll two groups of individuals: 1) patients who have either IPAH or a secondary form known to have similar histopathology (PAH), and 2) age, gender, and race matched control subjects for each patient Main: The main study will enroll three groups of individuals: 1) patients who have either IPAH or a secondary form known to have similar histopathology (PAH), 2) patients with PH ascribed to a nonvascular injury process, and 3) age, gender, and race matched control subjects for each PAH patient. Subjects must be at least 18 years of age and must be able to provide informed, written consent for participation in this study. There is no based on race or gender FOR The for this study are as follows Patients diagnosed with IPAH Patients diagnosed with secondary pulmonary hypertension known to have histopathology similar to the primary form or PAH. Clinical conditions causing pulmonary hypertension with histopathology similar to the primary form are listed below i. Eisenmenger Syndrome ii. Collagen vascular disease iii Liver disease with portal hypertension iv. Toxin induced injury (anorexic agents, rapeseed oil)  FOR WITH Pregnant women (all women of childbearing age will be required to have a screening urine or blood pregnancy test) Age less than 18 years Inability to provide informed written consent for participation in the study Mean PA less than or equal to 25mmHg or PVR less than 3 wood units PCW greater than 16 mmHg unless increase accounted for by increased transpulmonary gradient greater than or equal to 10 mmHg Patients receiving more than 1 year of oral therapy or more than 6 months of IV therapy FOR WITH The are as follows Patients diagnosed with pulmonary hypertension not known to have histopathology similar to the primary form. Etiologies are listed below
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 80.0-999.0,  Hypertension Aged 80 or older Sitting systolic BP 160-199 mmHg AND sitting diastolic BP < 110 mmHg  Known accelerated hypertension (retinal haemorrhages or exudates or papilloedema) Overt clinical congestive heart failure requiring treatment with a diuretic or angiotensin converting enzyme inhibitor. Subjects allowed if treated with digoxin only Renal failure (serum creatinine of more than 150 µmol/l) Previous documented cerebral or subarachnoid haemorrhage in the last 6 months. (Ischaemic cerebral and cardiac events do not although the patient must be neurologically and cardiologically stable.) Condition expected to severely limit survival, e.g. terminal illness Known secondary hypertension (e.g. renal artery stenosis, chronic renal insufficiency, and endocrine cause) Gout Clinical diagnosis of dementia Resident in a nursing home, i.e. where the dependency and care requirements of the patients are such that they require the regular input of qualified nurses and therefore the majority of staff in the home are nurses (other forms of residential care are acceptable) Unable to stand up or walk
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Brain Infarction Hypertension Patients with essential hypertension (systolic blood pressure>=140 mmHg and/or diastolic blood pressure>=90, or treated with antihypertensive drugs) Patients with any finding of stroke, silent brain infarction, and white matter lesion on magnetic resonance imaging  Secondary hypertension Atrial fibrillation History or signs of cerebral disorders other than cerebrovascular disease Malignant tumor Chronic renal failure Severe congestive heart failure Hyperkalemia Stenosis of bilateral renal artery
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 21.0-85.0,  Albuminuria Mild to moderate hypertension Type 2 diabetes mellitus Presence of protein in the urine (albuminuria)  Kidney disease not caused by diabetes or hypertension Renal artery stenosis Myocardial infarction or stroke within the last 6 months Type 1 diabetes mellitus Pregnant or lactating females Cancer within the last 5 years
Patient description: Karen is a 72-year-old woman with hypertension and type 2 diabetes, who was hospitalized for cryptogenic stroke two weeks ago. At the time, computed tomography was negative for brain hemorrhage and she was given thrombolytic therapy with resolution of her symptoms. Transesophageal echocardiogram and magnetic resonance angiogram of brain and great vessels found no evidence of abnormalities. She presents currently with a blood pressure of 120/70 mm Hg, normal glucose, and normal sinus rhythm on a 12-lead electrocardiogram. She reports history of occasional palpitations, shortness of breath and chest pain lasting for a few minutes and then stopping on their own.

Clinical trial eligibility criteria: eligible ages (years): 70.0-85.0,  Aged Systolic Hypertension Outpatients aged over 70 years and less than 85 years, regardless of sex Patients with stable seated systolic blood pressure of over 160 mmHg and diastolic blood pressure of less than 90 mmHg at two visits within 2 to 4 weeks Previously untreated patients or patients who are on other therapy that can be converted to valsartan  Patients with secondary hypertension or malignant hypertension Patients with seated systolic blood pressure of over 200 mmHg Patients with seated diastolic blood pressure of over 90 mmHg Patients with a history of cerebrovascular disorder or myocardial infarction within 6 months prior to enrolment in the study Patients who underwent coronary arterioplasty within 6 months prior to enrolment in the study or patients who will undergo coronary arterioplasty within 6 months after entry Patients with severe heart failure (NYHA functional classification III and IV) Patients with severe aortic stenosis or valvular disease Patients with atrial fibrillation, atrial flutter, or serious arrhythmia Patients with renal dysfunction with serum creatinine level of over 2 mg/dL Patients with serious liver dysfunction